¼­ºñ½º¾È³» ȸ¿ø°¡ÀÔ È¸¿øÅ»Åð Áñ°Üã±âµî·Ï
Home Products Company Directory Trade ÇÑÁßÇÕÀÛ Áß±¹ÅõÀÚ
My ChemNet
   ÇöÀçÀ§Ä¡ : Home > Trade
¡¡
¿ÀÆÛ°Ô½ÃÆÇ
Offer to Buy
Offer to Sell







ÀÔ·ÂÀÏÀÚ: 2018-04-08

Á¦¸ñ: Raloxifene hydrochloride
  µî·ÏºÐ·ù: Offer to Sell
  ³»¿ë: CAS NO: 82640-04-8
Price: 1USDMetric Tons
Payment: Western Union,Moneygram,banktransfer,bitcoin

Additional_detail: Product Description: CAS: 82640-04-8 M.F.: C28H28ClNO4S M.W. :510.04 Purity:99.8% M.P.: 250-253¡ÆC EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S.HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water. EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide. Usage: Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis. in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk,

¿¬¶ôó
´ã ´ç ÀÚ:
Cassie
ȸ»çÁÖ¼Ò:
Zhuzhou
ÀüÈ­¹øÈ£:
+8618188938020
ÆÑ½º¹øÈ£:
027-68886696-899 
E - mail:
sales03@ycgmp.com

Copyright © 2003-2015 ChemNet.com All Right Reserved.